Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Conclusions:
PPV could be feasible for mrTNBC patients because of the safety, immune responses, and possible clinical benefits.Clinical Trial Registration Number: UMIN000001844 (Registration Date: April 5, 2009)

Source: Breast Cancer Research - July 3, 2014 Category: Cancer & Oncology Authors: Ryuji TakahashiUhi TohNobutaka IwakumaMiki TakenakaHiroko OtsukaMina FurukawaTeruhiko FujiiNaoko SekiAkihiko KawaharaMasayoshi KageSatoko MatsuedaYoshito AkagiAkira YamadaKyogo ItohTetsuro Sasada Source Type: research